Saturday, July 4, 2015

Endo, GlaxoSmithKline announce senior management changes

Endo has hired a new chief operating officer, while GlaxoSmithKline has announced a succession plan for its vaccines business.

Endo, GlaxoSmithKline announce senior management changes


Two area drug companies announced changes to their management teams on Friday.

Endo Pharmaceuticals Holdings Inc. hired Julie McHugh as chief operating officer of the Chadds Ford company. Most recently, McHugh had been president and CEO of Nora Therapeutics, a venture-backed start-up.

But before that McHugh had been president of Centocor Inc., the Horsham-based biotech firm owned by Johnson & Johnson.

Endo president and CEO David Holveck also ran Centocor, prior to McHugh, when it was acquired by J&J in 1999.

GlaxoSmithKline P.L.C. unveiled a succession plan for its vaccines business, which is based in Rixensart, Belgium, and has a manufacturing plant in Marietta, Lancaster County.

Jean Stephenne was named chairman of GSK Biologicals, adding the title to his current responsibilities as president.

The pharmaceutical company, which employs several thousand in the Philadelphia region including at its Upper Merion research complex, said that operations of the business unit will be transitioned to Moncef Slaoui over the next two years. Slaoui has been chairman of research and development since June 2006.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter